Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery bleeding breakthrough? new study tests Desmopressin's Clot-Boosting power

NCT ID NCT07179991

Knowledge-focused Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how desmopressin, a drug that helps blood clot, affects platelet function in 100 adults undergoing heart surgery with a heart-lung machine. Researchers will use a special blood test called TEG6s to measure clotting at several time points before and after giving desmopressin. The goal is to better understand how the drug works and whether it can reduce the need for blood transfusions after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Desmopressin (DDAVP)
What this could lead to
If successful, this could help doctors better understand how desmopressin improves clotting, potentially reducing blood transfusions in heart surgery patients.
What could go wrong
This is a small, early-stage observational study focused on measuring effects, not proving clinical outcomes. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a prospective, observational, single centre study being conducted at London Health Sciences Centre (LHSC) with adults undergoing elective cardiac surgery with cardiopulmonary bypass to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years and above 2. Undergoing elective cardiac surgery with cardiopulmonary bypass 3. Able to provide informed consent Exclusion Criteria: 1. Hyponatremia 2. Allergy to desmopressin or its components 3. History of coronary artery disease with thrombosis 4. Recent history of thromboembolic events (Stroke/TIA/DVTs) 5. Severe Renal Impairment Creatinine Clearance\<30 ml/min 6. Inability to communicate in the English language

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraoperative bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Blood Loss, Surgical

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraoperative bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.